Gilead Sciences (GILD) Harvoni NRx Flat Week-Over-Week - RBC Citing IMS
Get Alerts GILD Hot Sheet
Rating Summary:
24 Buy, 16 Hold, 2 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) week 6 Harvoni TRx was 4366, according to RBC, citing IMS. Harvoni NRx was 3008, flat week-over-week. Harvoni+Sovaldi TRx was 7813, and NRx was 3996 down 2% week-over-week.
"Harvoni's week 6 NRx is tracking in line with our estimates in our HarvoniAPP and towards Q4 consensus of ~$3B US," said analyst Michael Yee.
"IMS also announced that some Oct data for Harvoni was understated due to a bridging error and will be corrected next year. But Nov data is back to normal, and thus we expect impact to be minimal as Nov and Dec will comprise the bulk share of Rxs this Q," he added.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $100.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)
- Omega Healthcare Investors (OHI) PT Raised to $32 at Citi
- Harvard Bioscience Inc. (HBIO) PT Raised to $6.75 at Singular Research
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!